Patents by Inventor Ahmad Hashash

Ahmad Hashash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210188830
    Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I. Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).
    Type: Application
    Filed: December 29, 2020
    Publication date: June 24, 2021
    Inventors: Vasu Sethuraman, Ahmad Hashash, Song Xue, Robert C. Livingston, Kwame Wiredu Nti-Addae
  • Publication number: 20210053962
    Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Application
    Filed: January 10, 2019
    Publication date: February 25, 2021
    Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
  • Patent number: 10889577
    Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: January 12, 2021
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Vasu Sethuraman, Ahmad Hashash, Song Xue, Robert C. Livingston, Kwame Wiredu Nti-Addae
  • Publication number: 20190350863
    Abstract: The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 21, 2019
    Inventor: Ahmad Hashash
  • Publication number: 20190269619
    Abstract: The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.
    Type: Application
    Filed: November 22, 2016
    Publication date: September 5, 2019
    Inventors: Craig Anthony Dunbar, Vasu Sethuraman, Ahmad Hashash
  • Publication number: 20190169179
    Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I. Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).
    Type: Application
    Filed: July 6, 2017
    Publication date: June 6, 2019
    Inventors: Vasu Sethuraman, Ahmad Hashash, Song Xue, Robert C. Livingston, Kwame Wiredu Nti-Addae
  • Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Publication number: 20190084978
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 21, 2019
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Patent number: 9969730
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20170362230
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Publication number: 20170226104
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20160310559
    Abstract: The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Angelika Fretzen, Mark G. Currie, Ahmad Hashash, Mahendra Dedhiya, Yun Mo, Anil Chhettry, Matthew Miller, Ritesh Sanghvi, Mohammad Mafruhul Bari, Andreas Grill
  • Patent number: 9469635
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: October 18, 2016
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Patent number: 9409891
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 9, 2016
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Publication number: 20160185770
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 30, 2016
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Publication number: 20140309187
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Patent number: 8841340
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 23, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Publication number: 20140275547
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Henggin Cheng
  • Publication number: 20140051749
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 20, 2014
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi